| Bioactivity | BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation[1]. |
| CAS | 2131199-52-3 |
| Formula | C17H14FNO3S |
| Molar Mass | 331.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Huang YH, et al. Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia. Cell Chem Biol. 2024 Nov 21;31(11):1885-1898.e10. |
BPRMU191
CAS: 2131199-52-3 F: C17H14FNO3S W: 331.36
BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biase
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.